SlideShare una empresa de Scribd logo
1 de 1
Descargar para leer sin conexión
PRESS RELEASE (to be released Tuesday, 29 January 2013)

Accelera S.r.l to join the Discovery Summit 2013 at Le Méridien Beach Plaza | Monte-Carlo |
Monaco| 21-22 March 2013

marcus evans is pleased to announce the participation of Accelera as a Sponsor at the Discovery
Summit 2013 taking place at Le Méridien Beach Plaza | Monte-Carlo | Monaco 21-22 March 2013.

The Discovery Summit provides a unique and exclusive forum for global R&D professionals and drug
discovery sponsors to focus in an intimate environment on discussions around key new drivers
shaping discovery research and development today. More details about the Discovery Summit 2013
can be found here.

Accelera based in Nerviano, near Milan, Italy, is the non-clinical Contract Research Organization
(CRO) of choice as Drug Development Partner for pharmaceutical and biotechnology companies
around the world.
Accelera supports all stages of discovery and development by offering integrated services, including
Attrition Reducing Technologies (ART) and Toxicology Screening to help “pick the best” drug
candidates, as well as Regulatory Drug Safety, Safety Pharmacology, ADME, Bioanalysis and
Pharmacokinetic Studies to translate and develop new chemical entities and biologicals into novel
drugs.
At Accelera sponsors and partners will find a unique platform of integrated scientific, technological
and regulatory expertise, built on decades of experience in the international pharmaceutical industry
adding real value to R&D programmes.
In addition, Accelera Oncology is an initiative to provide support services and consultancy for the
development for small and large molecules as new Oncology drugs.
With Accelera, Experience results.
www.accelera.info

For further information on the Discovery Summit 2013 programme please contact
Ruth Abbott
Marketing PR & Communications Director
ruth.PRsummits@marcusevans.com
marcus evans

Más contenido relacionado

Destacado

Destacado (10)

Test1
Test1Test1
Test1
 
Testonee
TestoneeTestonee
Testonee
 
100 w led flood lights - www.ngtlight.com
100 w led flood lights - www.ngtlight.com100 w led flood lights - www.ngtlight.com
100 w led flood lights - www.ngtlight.com
 
bevagna&montefalco excursion sheet
bevagna&montefalco excursion sheetbevagna&montefalco excursion sheet
bevagna&montefalco excursion sheet
 
Licencias creative commons
Licencias creative commonsLicencias creative commons
Licencias creative commons
 
Test1.pptx
Test1.pptxTest1.pptx
Test1.pptx
 
Test1
Test1Test1
Test1
 
Künka nõlva kaldenurga mõõtmine
Künka nõlva kaldenurga mõõtmineKünka nõlva kaldenurga mõõtmine
Künka nõlva kaldenurga mõõtmine
 
Af atelier cuisine bamas samedi 28 juin 2014
Af atelier cuisine bamas samedi 28 juin 2014Af atelier cuisine bamas samedi 28 juin 2014
Af atelier cuisine bamas samedi 28 juin 2014
 
AGM flyer 2015 in house
AGM flyer 2015 in houseAGM flyer 2015 in house
AGM flyer 2015 in house
 

Más de Life Sciences Network marcus evans

The Power of Digital Measures in Clinical Trials - Erwin De beuckelaer, Jans...
The Power of Digital Measures in Clinical Trials  - Erwin De beuckelaer, Jans...The Power of Digital Measures in Clinical Trials  - Erwin De beuckelaer, Jans...
The Power of Digital Measures in Clinical Trials - Erwin De beuckelaer, Jans...Life Sciences Network marcus evans
 
Optimizing Clinical Trial Operations - Alexander Fetkovsky, SanaClis
Optimizing Clinical Trial Operations - Alexander Fetkovsky, SanaClisOptimizing Clinical Trial Operations - Alexander Fetkovsky, SanaClis
Optimizing Clinical Trial Operations - Alexander Fetkovsky, SanaClisLife Sciences Network marcus evans
 
How Sponsors and Vendors Can Form a True Partnership-Kristine Koontz, GSK
How Sponsors and Vendors Can Form a True Partnership-Kristine Koontz, GSKHow Sponsors and Vendors Can Form a True Partnership-Kristine Koontz, GSK
How Sponsors and Vendors Can Form a True Partnership-Kristine Koontz, GSKLife Sciences Network marcus evans
 
Technological Crossroads: Navigating the Intersection between Recruitment, Re...
Technological Crossroads: Navigating the Intersection between Recruitment, Re...Technological Crossroads: Navigating the Intersection between Recruitment, Re...
Technological Crossroads: Navigating the Intersection between Recruitment, Re...Life Sciences Network marcus evans
 
Beyond the Hype: Practical Approaches for Implementing Machine Learning and A...
Beyond the Hype: Practical Approaches for Implementing Machine Learning and A...Beyond the Hype: Practical Approaches for Implementing Machine Learning and A...
Beyond the Hype: Practical Approaches for Implementing Machine Learning and A...Life Sciences Network marcus evans
 
Keeping up with ICH E6(R2): Risk-Based Monitoring (RBM) Redefined
Keeping up with ICH E6(R2): Risk-Based Monitoring (RBM) RedefinedKeeping up with ICH E6(R2): Risk-Based Monitoring (RBM) Redefined
Keeping up with ICH E6(R2): Risk-Based Monitoring (RBM) RedefinedLife Sciences Network marcus evans
 
Turning Sponsor/CRO Relationships into Partnerships for Success
Turning Sponsor/CRO Relationships into Partnerships for SuccessTurning Sponsor/CRO Relationships into Partnerships for Success
Turning Sponsor/CRO Relationships into Partnerships for SuccessLife Sciences Network marcus evans
 
Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...
Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...
Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...Life Sciences Network marcus evans
 
Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...
Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...
Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...Life Sciences Network marcus evans
 
The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...
The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...
The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...Life Sciences Network marcus evans
 
Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...
Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...
Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...Life Sciences Network marcus evans
 
Individualizing Patient Care through Precision Medicine: Shaping the Industry...
Individualizing Patient Care through Precision Medicine: Shaping the Industry...Individualizing Patient Care through Precision Medicine: Shaping the Industry...
Individualizing Patient Care through Precision Medicine: Shaping the Industry...Life Sciences Network marcus evans
 
Collaboration between Industry and Academia – An Opportunity to Drive Efficie...
Collaboration between Industry and Academia – An Opportunity to Drive Efficie...Collaboration between Industry and Academia – An Opportunity to Drive Efficie...
Collaboration between Industry and Academia – An Opportunity to Drive Efficie...Life Sciences Network marcus evans
 
Considering the End before the Beginning: Choosing the Correct Endpoints - An...
Considering the End before the Beginning: Choosing the Correct Endpoints - An...Considering the End before the Beginning: Choosing the Correct Endpoints - An...
Considering the End before the Beginning: Choosing the Correct Endpoints - An...Life Sciences Network marcus evans
 
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...Life Sciences Network marcus evans
 
Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...
Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...
Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...Life Sciences Network marcus evans
 
Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...
Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...
Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...Life Sciences Network marcus evans
 
Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...
Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...
Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...Life Sciences Network marcus evans
 

Más de Life Sciences Network marcus evans (20)

The Power of Digital Measures in Clinical Trials - Erwin De beuckelaer, Jans...
The Power of Digital Measures in Clinical Trials  - Erwin De beuckelaer, Jans...The Power of Digital Measures in Clinical Trials  - Erwin De beuckelaer, Jans...
The Power of Digital Measures in Clinical Trials - Erwin De beuckelaer, Jans...
 
Optimizing Clinical Trial Operations - Alexander Fetkovsky, SanaClis
Optimizing Clinical Trial Operations - Alexander Fetkovsky, SanaClisOptimizing Clinical Trial Operations - Alexander Fetkovsky, SanaClis
Optimizing Clinical Trial Operations - Alexander Fetkovsky, SanaClis
 
How Sponsors and Vendors Can Form a True Partnership-Kristine Koontz, GSK
How Sponsors and Vendors Can Form a True Partnership-Kristine Koontz, GSKHow Sponsors and Vendors Can Form a True Partnership-Kristine Koontz, GSK
How Sponsors and Vendors Can Form a True Partnership-Kristine Koontz, GSK
 
Technological Crossroads: Navigating the Intersection between Recruitment, Re...
Technological Crossroads: Navigating the Intersection between Recruitment, Re...Technological Crossroads: Navigating the Intersection between Recruitment, Re...
Technological Crossroads: Navigating the Intersection between Recruitment, Re...
 
Beyond the Hype: Practical Approaches for Implementing Machine Learning and A...
Beyond the Hype: Practical Approaches for Implementing Machine Learning and A...Beyond the Hype: Practical Approaches for Implementing Machine Learning and A...
Beyond the Hype: Practical Approaches for Implementing Machine Learning and A...
 
Keeping up with ICH E6(R2): Risk-Based Monitoring (RBM) Redefined
Keeping up with ICH E6(R2): Risk-Based Monitoring (RBM) RedefinedKeeping up with ICH E6(R2): Risk-Based Monitoring (RBM) Redefined
Keeping up with ICH E6(R2): Risk-Based Monitoring (RBM) Redefined
 
Turning Sponsor/CRO Relationships into Partnerships for Success
Turning Sponsor/CRO Relationships into Partnerships for SuccessTurning Sponsor/CRO Relationships into Partnerships for Success
Turning Sponsor/CRO Relationships into Partnerships for Success
 
Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...
Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...
Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...
 
Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...
Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...
Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...
 
The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...
The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...
The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...
 
Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...
Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...
Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...
 
Individualizing Patient Care through Precision Medicine: Shaping the Industry...
Individualizing Patient Care through Precision Medicine: Shaping the Industry...Individualizing Patient Care through Precision Medicine: Shaping the Industry...
Individualizing Patient Care through Precision Medicine: Shaping the Industry...
 
Collaboration between Industry and Academia – An Opportunity to Drive Efficie...
Collaboration between Industry and Academia – An Opportunity to Drive Efficie...Collaboration between Industry and Academia – An Opportunity to Drive Efficie...
Collaboration between Industry and Academia – An Opportunity to Drive Efficie...
 
Considering the End before the Beginning: Choosing the Correct Endpoints - An...
Considering the End before the Beginning: Choosing the Correct Endpoints - An...Considering the End before the Beginning: Choosing the Correct Endpoints - An...
Considering the End before the Beginning: Choosing the Correct Endpoints - An...
 
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
 
Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...
Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...
Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...
 
Business Development Activities Interview - Clinart MENA
Business Development Activities Interview - Clinart MENABusiness Development Activities Interview - Clinart MENA
Business Development Activities Interview - Clinart MENA
 
Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...
Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...
Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...
 
Where marcus evans fits in our business development mix
Where marcus evans fits in our business development mixWhere marcus evans fits in our business development mix
Where marcus evans fits in our business development mix
 
Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...
Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...
Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...
 

Accelera S.r.l to join the Discovery Summit 2013 at Le Méridien Beach Plaza, Monte-Carlo, Monaco, 21-22 March 2013

  • 1. PRESS RELEASE (to be released Tuesday, 29 January 2013) Accelera S.r.l to join the Discovery Summit 2013 at Le Méridien Beach Plaza | Monte-Carlo | Monaco| 21-22 March 2013 marcus evans is pleased to announce the participation of Accelera as a Sponsor at the Discovery Summit 2013 taking place at Le Méridien Beach Plaza | Monte-Carlo | Monaco 21-22 March 2013. The Discovery Summit provides a unique and exclusive forum for global R&D professionals and drug discovery sponsors to focus in an intimate environment on discussions around key new drivers shaping discovery research and development today. More details about the Discovery Summit 2013 can be found here. Accelera based in Nerviano, near Milan, Italy, is the non-clinical Contract Research Organization (CRO) of choice as Drug Development Partner for pharmaceutical and biotechnology companies around the world. Accelera supports all stages of discovery and development by offering integrated services, including Attrition Reducing Technologies (ART) and Toxicology Screening to help “pick the best” drug candidates, as well as Regulatory Drug Safety, Safety Pharmacology, ADME, Bioanalysis and Pharmacokinetic Studies to translate and develop new chemical entities and biologicals into novel drugs. At Accelera sponsors and partners will find a unique platform of integrated scientific, technological and regulatory expertise, built on decades of experience in the international pharmaceutical industry adding real value to R&D programmes. In addition, Accelera Oncology is an initiative to provide support services and consultancy for the development for small and large molecules as new Oncology drugs. With Accelera, Experience results. www.accelera.info For further information on the Discovery Summit 2013 programme please contact Ruth Abbott Marketing PR & Communications Director ruth.PRsummits@marcusevans.com marcus evans